HOUSTON, April 17, 2019 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors, today announced
that its ongoing sponsored research at The University of Texas MD Anderson Cancer Center has
now demonstrated that Annamycin is able to significantly improve
survival in an aggressive form of triple negative breast cancer
metastasized to the lungs in animal models.
"We know that Annamycin was previously shown to be significantly
more potent than doxorubicin in both Lewis lung carcinoma in
vivo and small cell lung cancer in vitro models,"
commented Walter Klemp, Moleculin's
Chairman and CEO. "Now we are seeing significant activity against
triple negative breast cancer that has metastasized to the lungs.
This particular animal model used in our testing is considered to
represent a very aggressive form of cancer. We believe our success
in increasing the survival rate in mice with this tumor model in
combination with the previously observed high uptake of Annamycin
by the lungs is a promising indication that supports additional
clinical research in lung and metastatic lung cancers."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of oncology drug candidates, all
of which are based on discoveries made at M.D. Anderson Cancer
Center. The Company's clinical stage drugs are Annamycin, an
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, and WP1066, an immuno-stimulating STAT3
inhibitor targeting brain tumors, pancreatic cancer and AML.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional STAT3 inhibitors
and compounds targeting the metabolism of tumors.
For more information about the Company, please visit
https://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Annamycin to
show safety and efficacy in patients. Although Moleculin Biotech
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Moleculin Biotech
has attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Contacts
Joe Dorame
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-significant-discovery-in-lung-cancer-models-300833462.html
SOURCE Moleculin Biotech, Inc.